Mark Purcell
Stock Analyst at Morgan Stanley
(1.03)
# 3,717
Out of 4,947 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $123.95 | -8.03% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $49.95 | +10.11% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $39.10 | +12.53% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $79.10 | +7.46% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $52.25 | +129.67% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $123.95
Upside: -8.03%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $49.95
Upside: +10.11%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $39.10
Upside: +12.53%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $79.10
Upside: +7.46%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $52.25
Upside: +129.67%